ALCJ.PA Crossject

Healthcare Health Care Equipment & Supplies Euronext Paris
1.23 EUR
Close of Nov 7, 2026
1.10 2.70
Market cap
EUR 74.7M
P/E
-
P/B
25.11x
ROE
-1,152.7%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALCJ.PA undervalued?

Graham number

The Graham number of Crossject cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Crossject fundamental analysis

1 of 11 checks passed

ROE 2/2

The stock's ROE exceeds expectations (798.35%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

ROA 0/2

The stock's ROA (-50.33%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 0/2

The stock's elevated P/BV ratio (59.41x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 0/2

The company has a high debt to equity ratio (592%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 0/1

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 0/1

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Crossject stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Crossject

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In additio…

Full company profile